腹腔镜手术联合米非司酮/孕三烯酮治疗子宫内膜异位症临床观察

目的：探讨腹腔镜手术联合米非司酮或孕三烯酮治疗子宫内膜异位症的临床疗效。方法选取我院2011年6月～2013年6月149例子宫内膜异位症确诊患者，随机分为3组，治疗组为腹腔镜联合米非司酮组（n=60）和腹腔镜联合孕三烯酮组（n=60），对照组为单独腹腔镜治疗组（n=29）。比较各组临床治疗效果、术后复发、内分泌变化及副作用发生率等指标。结果与对照组相比，治疗组患者的有效率明显提高，差异均具有统计学意义（P＜0.05）。治疗组间治疗效果、内分泌指标（FSH、LH、P、E2等）及副作用发生率均无明显差异。结论腹腔镜手术联合米非司酮或孕三烯酮治疗子宫内膜异位症安全可靠、临床疗效好，适合临床推广。

Clinical observation of laparoscopic surgery combined with mifepristone/gestrinone in treatment of endometriosis

Objective To evaluate the clinical efficacy of laparoscopic surgery combined with mifepristone or gestrinone in the treatment of endometriosis. Methods 149 patients diagnosed with endometriosis in our hospital from June 2011 to June 2013 were selected and randomly divided into three groups. The treatment groups were the laparoscopy combined with mifepristone group（n=60） and the laparoscopy combined with gestrinone group（n=60）;The control group was the simple laparoscopic treatment group（n=29）. The clinical treatment effects, postoperative recurrence, endocrine changes, incidences of adverse effects and other indicators of the two groups were compared. Results The effective rates of the treatment groups increased significantly compared to the effective rate of the control group, with statistically significant differences（P 〈 0.05）.The two treatment groups were not significantly different in the between-group treatment effects, endocrine indicators（FSH, LH, P, E2, etc.） and incidences of side effects. Conclusion In the treatment of endometriosis, laparoscopic surgery combined with mifepristone or gestrinone is safe and reliable and shows preferable clinical efficacy, suitable for clinical promotion.